Results 141 to 150 of about 4,877,471 (249)

Supplemental Table S1 from Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis

, 2023
Christophe Martinaud, Christophe Desterke, Johanna Konopacki, Lisa Pieri, Fréderic Torossian, Rachel Golub, Sandrine Schmutz, Adrienne Anginot, Bernadette Guerton, Nathalie Rochet, Patricia Albanese, Emilie Hénault, Olivier Pierre-Louis, Jean-Baptiste Souraud, Thierry de Revel, Brigitte Dupriez, Jean‐Christophe Ianotto, Marie‐Françoise Bourgeade, Alessandro M. Vannucchi, Jean‐Jacques Lataillade, Marie‐Caroline Le Bousse‐Kerdilès   +20 more
openalex   +2 more sources

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome

Clinics, 2013
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.
Bruno Deltreggia Benites, Carolina Silva Costa Lima, Irene Lorand-Metze, Marcia Torresan Delamain, Gislaine Borba Oliveira, Daiane de Almeida, Carmino Antonio de Souza, Jose Vassallo, Katia Borgia Barbosa Pagnano   +8 more
doaj  

Can somatic GATA2 mutation mimic germ line GATA2 mutation? [PDF]

, 2018
Somatic GATA2 mutation is associated with immunodeficiency and pulmonary alveolar proteinosis in a patient with myeloproliferative ...
Collin, M, Dickinson, R, Lipman, M, Lowe, D, Marafioti, T, Mitchell, C, Pocock, R, Sekhar, M   +7 more
core  

Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. [PDF]

, 2018
Ataxia-telangiectasia confers a significant increase in the development of several cancer types, most commonly leukemia and lymphoma. However, as the natural history for these patients is evolving and their lifespan is increasing, there is the potential ...
Bateni, Cyrus P, Canter, Robert J, Darrow, Morgan A, Evans, Christopher P, Judge, Sean James, Plescia, Trevor A   +5 more
core  

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study

Therapeutic Advances in Hematology
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease.
Han Xu, Yujie Xu, Mengying Wang, Chunxia Mao, Junxia Huang, Tianlan Li, Yan Gao, Shanshan Liu, Jingjing Zhou, Yi Zhang, Xianqi Feng   +10 more
doaj   +1 more source

Rare congenital chromosomal aberration dic(X;Y)(p22.33;p11.32) in a patient with primary myelofibrosis [PDF]

, 2016
Lenka Pavlištová, Silvia Izáková, Zuzana Zemanová, Lucie Bartuskova, Martina Langová, Pavlína Malíková, K Michalová   +6 more
openalex   +1 more source

MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? [PDF]

, 2019
Accurso, V., Cordova, A., Di Piazza, F., Di Stefano, A. B., Lo Re, J., Mancuso, S., Russo, A., Santoro, M., Siragusa, S.   +8 more
core   +1 more source

Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications [PDF]

, 2015
Aziz Nazha, Joseph D. Khoury, Raajit K. Rampal, Naval Daver   +3 more
openalex   +1 more source

Circulating megakaryocyte in primary myelofibrosis: an uncommon finding in a myelofibrosis blood smear

, 2021
Pedro Asensi Cantó, María Leonor Senent Peris, Elvira Mora   +2 more
openalex   +2 more sources

JAK-2 inhibitors and allogeneic transplant in myelofibrosis [PDF]

, 2015
7The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce splenomegaly and symptoms in patients affected by myelofibrosis, leading to a ...
Cigana, C, De Marchi, R, Fanin, Renato, Lazzarotto, D, Patriarca, Francesca, Perali, G, Sperotto, A   +6 more
core